{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:41:51Z","timestamp":1793295711883,"version":"4.5.0"},"reference-count":61,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T00:00:00Z","timestamp":1683763200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2023,12,31]]},"DOI":"10.1080\/13696998.2023.2207413","type":"journal-article","created":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T18:31:54Z","timestamp":1682533914000},"page":"667-678","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":8,"title":["Real-world treatment patterns and healthcare resource utilization among migraine patients: a German claims database analysis"],"prefix":"10.1080","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9362-3711","authenticated-orcid":false,"given":"Charly","family":"Gaul","sequence":"first","affiliation":[{"name":"Headache Center Frankfurt, Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2682-5620","authenticated-orcid":false,"given":"Karolin","family":"Seidel","sequence":"additional","affiliation":[{"name":"Xcenda GmbH, Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Heuck","sequence":"additional","affiliation":[{"name":"AbbVie Deutschland GmbH &amp; Co. KG, Wiesbaden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmina","family":"Silaidos","sequence":"additional","affiliation":[{"name":"AbbVie Deutschland GmbH &amp; Co. KG, Wiesbaden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thora","family":"Mrosowsky","sequence":"additional","affiliation":[{"name":"AbbVie Deutschland GmbH &amp; Co. KG, Wiesbaden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Eberhardt","sequence":"additional","affiliation":[{"name":"Former employee of AbbVie Deutschland GmbH &amp; Co. KG, Wiesbaden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Fritz","sequence":"additional","affiliation":[{"name":"AbbVie Deutschland GmbH &amp; Co. KG, Wiesbaden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6960-728X","authenticated-orcid":false,"given":"Christian","family":"Jacob","sequence":"additional","affiliation":[{"name":"Xcenda GmbH, Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,5,11]]},"reference":[{"key":"e_1_3_9_2_1","doi-asserted-by":"crossref","unstructured":"Diener H-C F\u00f6rderreuther S Kropp P. Therapie der Migr\u00e4neattacke und Prophylaxe der Migr\u00e4ne S1-Leitlinie [Migraine attack therapy and migraine prophylaxis S1 guideline]. Berlin: Deutsche Gesellschaft f\u00fcr Neurologie [German Society for Neurology]; 2022. Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie [Guidelines for diagnostics and therapy in neurology]; AWMF register number: 030\/057. German. Available from: https:\/\/dgn.org\/leitlinie\/118.","DOI":"10.1007\/s42451-023-00550-2"},{"key":"e_1_3_9_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01208-0"},{"key":"e_1_3_9_4_1","doi-asserted-by":"publisher","DOI":"10.1017\/cjn.2021.75"},{"key":"e_1_3_9_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2011.03612.x"},{"key":"e_1_3_9_6_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102420944842"},{"key":"e_1_3_9_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-021-01243-5"},{"key":"e_1_3_9_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13969"},{"key":"e_1_3_9_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2009.02748.x"},{"key":"e_1_3_9_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-018-0839-1"},{"key":"e_1_3_9_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-019-1027-7"},{"key":"e_1_3_9_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01154-x"},{"key":"e_1_3_9_13_1","unstructured":"World Health Organization. Atlas of headache disorders and resources in the world 2011. Geneva: World Health Organization; 2011. Available from: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/44571\/9789241564212_eng.pdf?sequence=1&isAllowed=y."},{"key":"e_1_3_9_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-019-1034-8"},{"key":"e_1_3_9_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2008.01263.x"},{"key":"e_1_3_9_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.12055"},{"key":"e_1_3_9_17_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102416678382"},{"key":"e_1_3_9_18_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102414547138"},{"key":"#cr-split#-e_1_3_9_19_1.1","unstructured":"Allergan Inc. : BOTOX\u00ae von Allergan feiert 25 Jahre Zulassung in Deutschland [BOTOX\u00ae from Allergan celebrates 25 years of approval in Germany] Internet]2018. updated 2018 Dec 5"},{"key":"#cr-split#-e_1_3_9_19_1.2","unstructured":"cited 2022 Mar 30]. German. Available from: https:\/\/www.allergan.de\/de-de\/news\/news\/botox-allergan-celebrates-25-years.aspx."},{"key":"e_1_3_9_20_1","unstructured":"AbbVie Ltd: BOTOX 100 Units: Summary of product characteristics [Internet]. Randalls Way Leatherhead (UK): Datapharm Ltd; 2022. [updated 2022 May 23; cited 2023 Jan 20]. Available from: https:\/\/www.medicines.org.uk\/emc\/medicine\/112."},{"key":"e_1_3_9_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102410364676"},{"key":"e_1_3_9_22_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102410364677"},{"key":"e_1_3_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32504-8"},{"key":"#cr-split#-e_1_3_9_24_1.1","unstructured":"Gemeinsamer Bundesausschuss [Federal Joint Committee]: Nutzenbewertungsverfahren zum Wirkstoff Erenumab (Migr\u00e4ne-Prophylaxe) [Benefit assessment procedure for the active substance erenumab (migraine prophylaxis)] [Internet]. 2018. updated 2019 May 2"},{"key":"#cr-split#-e_1_3_9_24_1.2","unstructured":"cited 2023 Jan 20]. GermanAvailable from https:\/\/www.g-ba.de\/bewertungsverfahren\/nutzenbewertung\/411\/."},{"key":"#cr-split#-e_1_3_9_25_1.1","unstructured":"Gemeinsamer Bundesausschuss [Federal Joint Committee]: Nutzenbewertungsverfahren zum Wirkstoff Galcanezumab (Migr\u00e4ne-Prophylaxe) [Benefit assessment procedure for the active substance galcanezumab (migraine prophylaxis)] [Internet]. 2019. updated 2019 Sept 19"},{"key":"#cr-split#-e_1_3_9_25_1.2","unstructured":"cited 2023 Jan 20]. GermanAvailable from https:\/\/www.g-ba.de\/bewertungsverfahren\/nutzenbewertung\/450\/."},{"key":"#cr-split#-e_1_3_9_26_1.1","unstructured":"Gemeinsamer Bundesausschuss [Federal Joint Committee]: Nutzenbewertungsverfahren zum Wirkstoff Fremanezumab (Migr\u00e4ne-Prophylaxe) [Benefit assessment procedure for the active substance fremanezumab (migraine prophylaxis)] [Internet]. 2019. updated 2019 Nov 7"},{"key":"#cr-split#-e_1_3_9_26_1.2","unstructured":"cited 2023 Jan 20]. GermanAvailable from https:\/\/www.g-ba.de\/bewertungsverfahren\/nutzenbewertung\/462\/."},{"key":"#cr-split#-e_1_3_9_27_1.1","unstructured":"European Medicines Agency (EMA): EPAR product information - Vyepti eptinezumab Internet]2022. [updated 2022 Nov 29"},{"key":"#cr-split#-e_1_3_9_27_1.2","unstructured":"cited 2023 Jan 20]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/vyepti-epar-product-information_en.pdf."},{"key":"e_1_3_9_28_1","doi-asserted-by":"crossref","unstructured":"Diener H-C May A. Prophylaxe der Migr\u00e4ne mit monoklonalen Antik\u00f6rpern gegen CGRP oder den CGRP-Rezeptor Erg\u00e4nzung der S1-Leitlinie [Prophylaxis of migraine with monoclonal antibodies to CGRP or the CGRP receptor S1 guideline supplement.]. Berlin: Deutsche Gesellschaft f\u00fcr Neurologie [German Society for Neurology]; 2019. Leitlinien f\u00fcr die Therapie der Migr\u00e4neattacke und Prophylaxe der Migr\u00e4ne [Guidelines for migraine attack therapy and migraine prophylaxis]; AWMF register number: Supplement to 030\/057. German. Available from: https:\/\/dgn.org\/leitlinie\/154.","DOI":"10.1007\/s42451-020-00163-z"},{"key":"#cr-split#-e_1_3_9_29_1.1","unstructured":"Statistisches Bundesamt DESTATIS [Federal Office of Statistics]: Bev\u00f6lkerung nach Nationalit\u00e4t und Geschlecht [Population by nationality and sex] [Internet]2021. [updated 2021 June 21"},{"key":"#cr-split#-e_1_3_9_29_1.2","unstructured":"cited 2023 Jan 20]. German. Available from: https:\/\/www.destatis.de\/DE\/Themen\/Gesellschaft-Umwelt\/Bevoelkerung\/Bevoelkerungsstand\/Tabellen\/zensus-geschlecht-staatsangehoerigkeit-2020.html."},{"key":"e_1_3_9_30_1","unstructured":"Bundesministerium f\u00fcr Gesundheit : Kennzahlen der Gesetzlichen Krankenversicherung 2010 bis 2022 [Key figures for the statutory health insurance 2010 to 2022] [Internet]2022. [updated 2022 June; cited 2023 Jan 20]. German. Available from: https:\/\/www.bundesgesundheitsministerium.de\/fileadmin\/Dateien\/3_Downloads\/Statistiken\/GKV\/Kennzahlen_Daten\/KF2022Bund_Juni_2022.pdf."},{"key":"e_1_3_9_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3895"},{"key":"e_1_3_9_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.puhe.2022.02.013"},{"key":"#cr-split#-e_1_3_9_33_1.1","unstructured":"Bundesamt f\u00fcr Soziale Sicherung [Federal Office for Social Security]: Festlegungen nach \u00a7 8 Absatz 4 RSAV f\u00fcr das Ausgleichsjahr 2022. [Determinations pursuant to Section 8 (4) RSAV for the compensation year 2022] [Internet]. 2021 [updated 2021 Sep 30"},{"key":"#cr-split#-e_1_3_9_33_1.2","unstructured":"cited 2023 Jan 20]. German. Available from: https:\/\/www.bundesamtsozialesicherung.de\/fileadmin\/redaktion\/Risikostrukturausgleich\/Festlegungen\/2022\/03_Klassifikation_AJ2022_Festlegung.zip."},{"key":"#cr-split#-e_1_3_9_34_1.1","unstructured":"Kassen\u00e4rztliche Bundesvereinigung (KBV) [National Association of Statutory Health Insurance Physicians ]: Schl\u00fcsseltabellen S_BAR2_ARZTNRFACHGRUPPE (OID: 1.2.276.0.76.3.1.1.5.2.23) [Key tables S_BAR2_ARZTNRFACHGRUPPE (OID: 1.2.276.0.76.3.1.1.5.2.23)] [Internet]. 2019 [updated 2019 Apr 1"},{"key":"#cr-split#-e_1_3_9_34_1.2","unstructured":"cited 2023 Jan 20]. German. Available from: https:\/\/applications.kbv.de\/S_BAR2_ARZTNRFACHGRUPPE_V1.01.xhtml."},{"key":"#cr-split#-e_1_3_9_35_1.1","unstructured":"Kassen\u00e4rztliche Bundesvereinigung (KBV) [National Association of Statutory Health Insurance Physicians]: Vereinbarung von Qualit\u00e4tssicherungsma\u00dfnahmen nach \u00a7 135 Abs. 2 SGB V zur schmerztherapeutischen Versorgung chronisch schmerzkranker Patienten [Agreement on quality assurance measures in accordance with Section 135 (2) of the German Social Code Book V for pain therapy care for patients with chronic pain] [Internet]. 2004. [updated 2016 Oct 1"},{"key":"#cr-split#-e_1_3_9_35_1.2","unstructured":"cited 2023 Jan 20]. German. Available from: https:\/\/kbv.de\/media\/sp\/Schmerztherapie.pdf."},{"key":"e_1_3_9_36_1","unstructured":"Novartis Pharma GmbH. Dossier zur Nutzenbewertung gem\u00e4\u00df \u00a7 35a SGB V zu Erenumab (Aimovig\u00ae) - Modul 3A [Dossier for the benefit assessment according to Section 35a SGB V on erenumab (Aimovig\u00ae) - Module 3A]. 2018. German. Available from: https:\/\/www.g-ba.de\/downloads\/92-975-2732\/2018-10-22_Modul3A_Erenumab.pdf."},{"key":"e_1_3_9_37_1","unstructured":"Techniker Krankenkasse (TK). Kopfschmerzreport 2020 \u2013 Pr\u00e4valenz Pillen und Perspektiven [Headache Report 2020 - Prevalence Pills and Perspectives]. Hamburg: Techniker Krankenkasse; 2020. Kopfschmerzreport [Headache Report]. German. Available from: https:\/\/www.tk.de\/resource\/blob\/2088842\/66767380cf7cce49b345b06baa704019\/kopfschmerzreport-2020-data.pdf."},{"key":"e_1_3_9_38_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2019.01000"},{"issue":"4","key":"e_1_3_9_39_1","article-title":"Real-world treatment and associated healthcare resource use among migraine patients in Germany","volume":"4","author":"Hardtstock F","year":"2020","unstructured":"Hardtstock F, Katsarava Z, Wilke T, et\u00a0al. Real-world treatment and associated healthcare resource use among migraine patients in Germany. Ann Head Med. 2020;4:4.","journal-title":"Ann Head Med"},{"key":"e_1_3_9_40_1","unstructured":"Grobe T Steinmann S Szecsenyi J. BARMER Arztreport 2017 [BARMER Physician Report 2017]. Berlin: Barmer Ersatzkasse; 2017. Schriftenreihe zur Gesundheitsanalyse [Series of publications on health analysis]; Volume 1. German. Available from: https:\/\/www.barmer.de\/resource\/blob\/1026820\/40985c83a99926e5c12eecae0a50e0ee\/barmer-arztreport-2017-band-1-data.pdf."},{"issue":"6","key":"e_1_3_9_41_1","first-page":"1","article-title":"Migr\u00e4ne und Spannungskopfschmerz in Deutschland: Pr\u00e4valenz und Erkrankungsschwere im Rahmen der Krankheitslast-Studie BURDEN 2020 [migraine and tension headache in Germany: prevalence and disease severity in the BURDEN 2020 disease burden study]","volume":"5","author":"Porst M","year":"2020","unstructured":"Porst M, Wengler A, Leddin J, et\u00a0al. Migr\u00e4ne und Spannungskopfschmerz in Deutschland: Pr\u00e4valenz und Erkrankungsschwere im Rahmen der Krankheitslast-Studie BURDEN 2020 [migraine and tension headache in Germany: prevalence and disease severity in the BURDEN 2020 disease burden study]. J Health Monit. 2020;5(S6):1\u201326. German.","journal-title":"J Health Monit"},{"key":"e_1_3_9_42_1","unstructured":"Grobe T Szecsenyi J. BARMER Arztreport 2021 [BARMER Physician Report 2021]. Berlin: Barmer Ersatzkasse; 2021. Schriftenreihe zur Gesundheitsanalyse [Series of publications on health analysis]; Volume 27. German. Available from: https:\/\/www.barmer.de\/resource\/blob\/1027518\/043d9a7bf773a8810548d18dec661895\/barmer-arztreport-2021-band-27-bifg-data.pdf."},{"key":"#cr-split#-e_1_3_9_43_1.1","unstructured":"European Medicines Agency (EMA): EPAR product information - Aimovig erenumab Internet]2018. [updated 2022 Mar 1"},{"key":"#cr-split#-e_1_3_9_43_1.2","unstructured":"cited 2023 Jan 20]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/aimovig-epar-product-information_en.pdf."},{"key":"#cr-split#-e_1_3_9_44_1.1","unstructured":"European Medicines Agency (EMA): EPAR product information - Ajovy fremanezumab Internet]2019. updated 2022 June 7"},{"key":"#cr-split#-e_1_3_9_44_1.2","unstructured":"cited 2023 Jan 20]. Available from https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ajovy-epar-product-information_en.pdf."},{"key":"#cr-split#-e_1_3_9_45_1.1","unstructured":"European Medicines Agency (EMA): EPAR product information - Emgality galcanezumab Internet]2019. updated 2022 Nov 11"},{"key":"#cr-split#-e_1_3_9_45_1.2","unstructured":"cited 2023 Jan 20]. Available from https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/emgality-epar-product-information_en.pdf."},{"key":"e_1_3_9_46_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01099-1"},{"key":"e_1_3_9_47_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-021-01316-5"},{"key":"e_1_3_9_48_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2021.1953301"},{"key":"#cr-split#-e_1_3_9_49_1.1","unstructured":"Gemeinsamer Bundesausschuss [Federal Joint Committee]: Beschluss zur Arzneimittel-Richtlinie\/Anlage VI: Off-Label-Use Aktualisierung Teil A Ziffer V Valproins\u00e4ure bei der Migr\u00e4neprophylaxe im Erwachsenenalter [Decision on the Guideline on Medicinal Products\/Annex VI: Off-Label Use Update Part A Item V Valproic Acid in the Prophylaxis of Migraine in Adults] [Internet]. 2020. [updated 2020 Aug 1"},{"key":"#cr-split#-e_1_3_9_49_1.2","unstructured":"cited 2023 Jan 20]. German. Available from: https:\/\/www.g-ba.de\/beschluesse\/4212\/."}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2023.2207413","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T07:45:27Z","timestamp":1729323927000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2023.2207413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,11]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,12,31]]}},"alternative-id":["10.1080\/13696998.2023.2207413"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2023.2207413","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,11]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-02-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}